Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1

Virology Journal

Volumn 8, Issue , 2011, Pages

  Lara, Humberto H ^a   Ixtepan Turrent, Liliana ^a   Garza Trevĩo, Elsa N ^a   Flores Tevĩo, Samantha M ^a   Borkow, Gadi ^b   Rodriguez Padilla, Cristina ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b Hama'Ayan 4   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

5,5' DITHIOBIS(2 NITROBENZOIC ACID); AMPRENAVIR; BACITRACIN; ENFUVIRTIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; CELL MEMBRANE; CELL PROTECTION; CONTROLLED STUDY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; NONHUMAN; VIRUS ENTRY; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSIOLOGY; T LYMPHOCYTE; TUMOR CELL LINE; VIRAL TROPISM; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; BACITRACIN; CELL LINE, TUMOR; DITHIONITROBENZOIC ACID; HIV INFECTIONS; HIV-1; HUMANS; T-LYMPHOCYTES; VIRAL TROPISM; VIRUS INTERNALIZATION;

EID: 79953100968     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-137     Document Type: Article

References (38)

1. The AIDS epidemic - considerations for the 21st century. AS Fauci, N Engl J Med 1999 341 14 1046 1050 10.1056/NEJM199909303411406 10502595 (Pubitemid 29451801)
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. FJ Palella Jr KM Delaney AC Moorman,, et al. N Engl J Med 1998 338 13 853 860 10.1056/NEJM199803263381301 9516219 (Pubitemid 28135961)
3. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. E Vittinghoff S Scheer P O'Malley G Colfax SD Holmberg SP Buchbinder, J Infect Dis 1999 179 3 717 720 10.1086/314623 9952385 (Pubitemid 30016162)
4. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. J Balzarini L Naesens E Verbeken,, et al. AIDS 1998 12 10 1129 1138 10.1097/00002030-199810000-00004 9677161 (Pubitemid 28302414)
5. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. AS Fauci, Science 1993 262 5136 1011 1018 10.1126/science.8235617 8235617 (Pubitemid 24035036)
6. The role of lymphoid organs in the pathogenesis of HIV infection. G Pantaleo C Graziosi AS Fauci, Semin Immunol 1993 5 3 157 163 10.1006/smim.1993.1019 8102261
7. Microbicides and barrier methods in HIV prevention. DL Van ZF Rosenberg, AIDS 1999 13 Suppl A 85 S92 10885766
8. Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. HJ Ryser EM Levy R Mandel GJ DiSciullo, Proc Natl Acad Sci USA 1994 91 10 4559 4563 10.1073/pnas.91.10.4559 8183947
9. Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry. A Gallina TM Hanley R Mandel,, et al. J Biol Chem 2002 277 52 50579 50588 10.1074/jbc.M204547200 12218051 (Pubitemid 36042217)
10. Protein disulfide isomerase (PDI) associates with NADPH oxidase and is required for phagocytosis of Leishmania chagasi promastigotes by macrophages. CX Santos BS Stolf PV Takemoto,, et al. J Leukoc Biol 2009 86 4 989 998 10.1189/jlb.0608354 19564574
11. Sequence of protein disulphide isomerase and implications of its relationship to thioredoxin. JC Edman L Ellis RW Blacher RA Roth WJ Rutter, Nature 1985 317 6034 267 270 10.1038/317267a0 3840230 (Pubitemid 16246506)
12. Protein disulfide isomerase and assisted protein folding. HF Gilbert, J Biol Chem 1997 272 47 29399 29402 10.1074/jbc.272.47.29399 9367991 (Pubitemid 27508016)
13. HIV entry and its inhibition. DC Chan PS Kim, Cell 1998 93 5 681 684 10.1016/S0092-8674(00)81430-0 9630213 (Pubitemid 28257575)
14. The catalytic activity of protein disulfide isomerase is involved in human immunodeficiency virus envelope-mediated membrane fusion after CD4 cell binding. E Fenouillet R Barbouche J Courageot R Miquelis, J Infect Dis 2001 183 5 744 752 10.1086/318823 11181151 (Pubitemid 32171749)
15. Glycosaminoglycans and protein disulfide isomerase-mediated reduction of HIV Env. R Barbouche H Lortat-Jacob IM Jones E Fenouillet, Mol Pharmacol 2005 67 4 1111 1118 10.1124/mol.104.008276 15644496 (Pubitemid 40410411)
16. Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion. R Barbouche R Miquelis IM Jones E Fenouillet, J Biol Chem 2003 278 5 3131 3136 10.1074/jbc.M205467200 12218052 (Pubitemid 36801223)
17. Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. I Markovic TS Stantchev KH Fields,, et al. Blood 2004 103 5 1586 1594 10.1182/blood-2003-05-1390 14592831 (Pubitemid 38268946)
18. Progress in targeting HIV-1 entry. HJ Ryser R Fluckiger, Drug Discov Today 2005 10 16 1085 1094 10.1016/S1359-6446(05)03550-6 16182193
19. Molecular docking studies of dithionitrobenzoic acid and its related compounds to protein disulfide isomerase: computational screening of inhibitors to HIV-1 entry. U Gowthaman M Jayakanthan D Sundar, BMC Bioinformatics 2008 9 Suppl 12 14 10.1186/1471-2105-9-S12-S14 19091013
20. Modulating proteostasis: peptidomimetic inhibitors and activators of protein folding. F Hatahet LW Ruddock, Curr Pharm Des 2009 15 21 2488 2507 10.2174/138161209788682343 19601846
21. A bioassay for HIV-1 based on Env-CD4 interaction. V Ciminale BK Felber M Campbell GN Pavlakis, AIDS Res Hum Retroviruses 1990 6 11 1281 1287 2078409
22. Approaches to the design of effective HIV-1 protease inhibitors. F Lebon M Ledecq, Curr Med Chem 2000 7 4 455 477 10702619 (Pubitemid 30396436)
23. Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion. R Barbouche R Miquelis IM Jones E Fenouillet, J Biol Chem 2003 278 5 3131 3136 10.1074/jbc.M205467200 12218052 (Pubitemid 36801223)
24. Inhibition of a reductive function of the plasma membrane by bacitracin and antibodies against protein disulfide-isomerase. R Mandel HJ Ryser F Ghani M Wu D Peak, Proc Natl Acad Sci USA 1993 90 9 4112 4116 10.1073/pnas.90.9.4112 8387210 (Pubitemid 23134176)
25. Net positive charge of HIV-1 CRF01-AE V3 sequence regulates viral sensitivity to humoral immunity. S Naganawa M Yokoyama T Shiino,, et al. PLoS One 2008 3 9 3206 10.1371/journal.pone.0003206 18787705
26. T-tropic sequence of the V3 loop is critical for HIV-1 infection of CXCR4-positive colonic HT-29 epithelial cells. JR Trujillo NV Goletiani I Bosch,, et al. J Acquir Immune Defic Syndr 2000 25 1 1 10 10.1097/00042560- 200009010-00001 11064498
27. Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells. JR Trujillo RA Rogers JD Brain, Virology 1998 246 1 53 62 10.1006/viro.1998.9185 9656993 (Pubitemid 28384059)
28. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. QE Yang AG Stephen JW Adelsberger,, et al. J Virol 2005 79 10 6122 6133 10.1128/JVI.79.10.6122-6133. 2005 15857997 (Pubitemid 40617217)
29. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Kimpton M Emerman, J Virol 1992 66 4 2232 2239 1548759
30. Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. PL Jones T Korte R Blumenthal, J Biol Chem 1998 273 1 404 409 10.1074/jbc.273.1.404 9417096 (Pubitemid 28042225)
31. Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors. A Hombrouck RB Van M Michiels,, et al. Antimicrob Agents Chemother 2008 52 8 2861 2869 10.1128/AAC.00210-08 18541726
32. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. M Witvrouw V Fikkert W Pluymers,, et al. Mol Pharmacol 2000 58 5 1100 1108 11040059
33. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT. J Auwerx M Stevens AR Van Rompay,, et al. J Virol 2004 78 14 7427 7437 10.1128/JVI.78.14.7427-7437.2004 15220416 (Pubitemid 38915888)
34. Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV action. M Stevens C Pannecouque CE De J Balzarini, Antimicrob Agents Chemother 2003 47 10 3109 3116 10.1128/AAC.47.10.3109-3116.2003 14506017 (Pubitemid 37229565)
35. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. ES Svarovskaia R Barr X Zhang,, et al. J Virol 2004 78 7 3210 3222 10.1128/JVI.78.7.3210-3222.2004 15016842 (Pubitemid 38568261)
36. Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors. X Zhang GC Pais ES Svarovskaia,, et al. Bioorg Med Chem Lett 2003 13 6 1215 1219 10.1016/S0960-894X(03)00059-3 12643946 (Pubitemid 36331834)
37. PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. HH Lara L Ixtepan-Turrent EN Garza-Trevino C Rodriguez-Padilla, J Nanobiotechnology 2010 8 15 10.1186/1477-3155-8-15 20626911
38. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. A Zussman L Lara HH Lara Z Bentwich G Borkow, AIDS 2003 17 5 653 661 10.1097/00002030-200303280-00002 12646787 (Pubitemid 36521071)